Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis

1996 ◽  
Vol 15 (1) ◽  
pp. 23-31 ◽  
Author(s):  
PEDRO A. PIEDRA ◽  
SUSAN GRACE ◽  
ALAN JEWELL ◽  
SUSAN SPINELLI ◽  
DAWN BUNTING ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Respiratory Syncytial Virus ◽  
Respiratory Tract ◽  
Fusion Protein ◽  
Lower Respiratory Tract ◽  
Protein Vaccine ◽  
Respiratory Syncytial Virus Season ◽  
Respiratory Tract Illness ◽  
Syncytial Virus

scholarly journals In SilicoApproach towards Designing Virtual Oligopeptides for HRSV

2014 ◽  
Vol 2014 ◽  
pp. 1-12 ◽  
Author(s):  
Ruchi Jain ◽  
Shanmughavel Piramanayagam
Keyword(s):  
Respiratory Syncytial Virus ◽  
Respiratory Tract ◽  
Virus Replication ◽  
Lower Respiratory Tract ◽  
Specific Interaction ◽  
Infection Process ◽  
Rational Choices ◽  
Respiratory Tract Illness ◽  
Syncytial Virus ◽  
Infants And Young Children

HRSV (human respiratory syncytial virus) is a serious cause of lower respiratory tract illness in infants and young children. Designing inhibitors from the proteins involved in virus replication and infection process provides target for new therapeutic treatments. In the present study,in silicodocking was performed using motavizumab as a template to design motavizumab derived oligopeptides for developing novel anti-HRSV agents. Additional simulations were conducted to study the conformational propensities of the oligopeptides and confirmed the hypothesis that the designed oligopeptide is highly flexible and capable of assuming stable confirmation. Our study demonstrated the best specific interaction of GEKKLVEAPKS oligopeptide for glycoprotein strain A among various screened oligopeptides. Encouraged by the results, we expect that the proposed scheme will provide rational choices for antibody reengineering which is useful for systematically identifying the possible ways to improve efficacy of existing antibody drugs.

Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis

Vaccine ◽  
2003 ◽  
Vol 21 (19-20) ◽  
pp. 2448-2460 ◽  
Author(s):  
Pedro A. Piedra ◽  
Stanley G. Cron ◽  
Alan Jewell ◽  
Nicole Hamblett ◽  
Ruth McBride ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Respiratory Syncytial Virus ◽  
Fusion Protein ◽  
Protein Vaccine ◽  
Syncytial Virus

Serious Early Childhood Wheezing After Respiratory Syncytial Virus Lower Respiratory Tract Illness in Preterm Infants

2010 ◽  
Vol 32 (14) ◽  
pp. 2422-2432 ◽  
Author(s):  
José R. Romero ◽  
Dan L. Stewart ◽  
Erin K. Buysman ◽  
Ancilla W. Fernandes ◽  
Hasan S. Jafri ◽  
...  
Keyword(s):  
Early Childhood ◽  
Respiratory Syncytial Virus ◽  
Respiratory Tract ◽  
Preterm Infants ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Illness ◽  
Syncytial Virus

Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis

1998 ◽  
Vol 17 (3) ◽  
pp. 217-224 ◽  
Author(s):  
PEDRO A. PIEDRA ◽  
SUSAN GRACE ◽  
ALAN JEWELL ◽  
SUSAN SPINELLI ◽  
DEBORAH A. HOGERMAN ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Respiratory Syncytial Virus ◽  
Fusion Protein ◽  
Protein Vaccine ◽  
Syncytial Virus
Sign in / Sign up

Export Citation Format

Share Document